Anemia is a common complication of chronic kidney disease (CKD). The prevalence of anemia varies with the degree of renal impairment in predialysis patients with CKD, but once end-stage kidney failure occurs, all patients are eventually affected (1) (2) (3) . Anemia develops once renal function decreases to Ͻ50% because of a deficiency in endogenous erythropoietin (EPO) production by the kidney, decreased red cell survival, blood losses, and increased red blood cell destruction once the patient begins dialysis treatment, particularly hemodialysis (4) .
Anemia reduces physical capacity, well-being, neurocognitive function, and energy level and worsens quality of life both in predialysis and dialysis patients (5) . Anemia also induces adaptive cardiovascular mechanisms to maintain tissue oxygen supply. This leads to left ventricular hypertrophy, left ventricular dilation, and myocardial ischemia, which are risk factors for cardiovascular disease and death (5, 6) . It is plausible that reversing anemia may reduce this risk (7) (8) (9) (10) .
Current treatment options for anemia include blood transfusion, recombinant human EPO (␣ or ␤) or darbepoetin ␣. The latter are growth factors for the bone marrow erythroid precursors, which stimulate production of erythrocytes (11, 12) . Treatment of anemia improves muscle strength and function, cardiac function, and cognitive and brain electrophysiologic function because of improved peripheral oxygen supply (10, 13) . Aspects of the patient's quality of life such as fatigue, depression, and relationships with others are better at higher hemoglobin (Hb) levels (5, 10, 14) , but higher Hb levels may also lead to an increased risk of arteriovenous fistula thrombosis, hypertension, and an increased number of adverse cardiovascular events. Also, reaching and maintaining higher Hb targets implies major costs (8, (15) (16) (17) (18) . Very recently, a number of trials in cancer patients were terminated prematurely because of unexpectedly higher mortality in the higher Hb groups, mainly as a result of disease progression and thromboembolic events (19) .
There has been a consistent trend toward higher Hb levels in dialysis patients of all ages, genders, and race categories during the past decade (2) . Guidelines have been developed for Hb targets, but there remains considerable debate regarding the appropriate Hb levels as shown by the wide variation that still exists in anemia management practices between and within countries ( Table 1 ). The aim of this systematic review is to summarize the benefits and harms of lower versus higher Hb targets in the treatment of the anemia of CKD using existing randomized, controlled trial data.
Materials and Methods

Inclusion Criteria
We included any randomized, controlled trial that was of at least 2 mo duration and assessed the effects of different Hb targets in pre-or postdialysis patients with anemia of CKD. The higher Hb target could be achieved by EPO (␣ or ␤) or darbepoetin ␣ or blood transfusion; the lower target could be achieved by lower doses of the same drugs or by a placebo or no treatment or blood transfusion.
Search Strategy
Electronic searches were performed in Medline (1966 ( through May 2003 and Embase (1988 through May 2003) using optimally sensitive search strategies for identification of randomized, controlled trials developed by the Cochrane Collaboration (20) . The Cochrane Renal Group Specialized Register was also searched. The following medical subject heading terms and text words were used: anemia, hemoglobin, hematocrit, CKD, renal replacement therapy, renal dialysis and hemofiltration, end stage renal disease, uremia, EPO, and darbepoetin. Trials were considered without language restriction. The results of these searches were analyzed in title and abstract form by one of the authors according to the inclusion criteria (G.F.M.S.). Reference lists from all identified articles were also searched. The conference proceedings of the American Society of Nephrology and European Dialysis and Transplantation Association meetings of 1999 to 2003 were searched for abstracts of relevant trials. Information about unpublished trials were sought from experts in the field, and pharmaceutical companies involved in the production of EPO and darbepoetin ␣ (Janssen-Cilag, Amgen, Roche) were approached for information about relevant trials.
Data Extraction and Quality Assessment
Each trial was assessed by two independent reviewers (G.F.M.S. and C.M.). From all included trials, data were extracted on characteristics of the study sample, doses and modalities of treatment, methodologic characteristics of the trials, and outcomes: all-cause mortality, left ventricular hypertrophy, cardiovascular mortality (myocardial infarction, stroke), adverse events (patients with hypertension requiring exclusion from study or administration of additional antihypertensive medication, seizures, access thrombosis, hyperkalemia), hospitalization rates and days of hospitalizations, renal function, BP, and quality of life.
Quality of the trials was assessed using standard criteria (allocation concealment, blinding, analysis by intention to treat, and completeness of follow-up) (21) . Any differences in data extraction were resolved by discussion among authors. When data were missing or incomplete, the authors of the trial were contacted for clarification.
Statistical Analyses
Dichotomous outcome data from individual trials were analyzed using the relative risk (RR) measure and its 95% confidence intervals (CI). The analysis was based on published event rates and took no account of the risk estimates provided by the trials, which in some cases could be adjusted for having performed interim analyses and other factors. When continuous outcome data were analyzed, difference in means and 95% CI at the end of treatment or difference in mean change between baseline and end of treatment value were calculated for individual trials. Subgroup analysis was planned to explore potential sources of variability in observed treatment effect when possible (overt or nonovert cardiovascular disease, time on dialysis, time on predialysis treatment). Heterogeneity of treatment effects between studies was formally tested using the Q (heterogeneity 2 ) and the I 2 statistics. When appropriate, summary estimators of treatment effects were calculated using the Der Simonian-Laird random-effects model with RR and its 95% CI for dichotomous outcomes and weighted mean difference with 95% CI for continuous outcomes (22) .
Results
The combined search of Medline, Embase, and the specialist registry of the Cochrane Renal Group identified 1365 articles, 1322 of which were excluded. The major reasons for exclusion were that selected studies were not randomized or were randomized trials that evaluated other interventions (e.g., subcutaneous versus intravenous EPO treatment for anemia of CKD) or because only surrogate and hemorheologic outcomes were reported (e.g., blood viscosity, hematopoietic progenitor cell assays; Figure 1 
Trial Characteristics
Two groups of studies were identified. In seven trials (2058 patients), the hypothesis of whether a higher and "normal" Hb target was better than a lower Hb target was tested. Patients were randomized to reach the two pre-established Hb targets. Generally a low EPO dose was administered to achieve a lower Hb target and a higher dose was administered to achieve a higher Hb target. However, in two of these trials, some patients in the low Hb target group received lower doses of EPO or no EPO at all (42, 43) . Overall, the achieved Hb values of the experimental arms in this group of trials were in the range of 119 to 150 g/L and the achieved Hb values of the control arm were in the range of 90 to 120 g/L. Of the seven studies in this group, the Besarab et al. (16) , Berns et al. (26) , and Conlon et al. (28) trials enrolled patients with severe cardiovascular disease (congestive heart failure or ischemic heart disease). The Besarab et al. (16) trial was terminated at the third interim analysis when differences in mortality between the groups were recognized as sufficient to make it very unlikely that continuation of the study would reveal a benefit for the higher Hb target group. There was also a significantly higher rate of vascular access loss in the higher Hb target group, indicating that patients in this group were experiencing harmful effects. (Table 2 ).
In the other 12 trials (638 patients), the tested hypothesis was a pharmacologic one; that is, whether EPO treatment compared with no EPO treatment was associated with improved outcomes. Patients who were randomized to placebo ended up having a lower Hb target of Ͻ95 g/L, whereas those who were randomized to EPO treatment achieved higher Hb levels of Ͼ100 g/L (15,23,24,27,30 -37) . Overall, the achieved Hb targets of the experimental arms in this group of trials were in the range of 95 to 133.3 g/L and the achieved Hb targets of the control arm were in the range of 75 to 104 g/L. The patients who were enrolled in this second group of trials had no overt cardiovascular comorbidity. The Canadian Erythropoietin Study Group trial had three arms: one of placebo, one of low-dose EPO, and one of high dose EPO. The Lim et al. (32) trial included four arms: one of placebo and three of different EPO doses.
In summary, the first group contained studies in which the intervention was to achieve different Hb targets, and trials included individuals with clinical cardiovascular disease. The The highest achieved targets are reported independent of specific subgroup (in this trial, target Hb values were presented separately for the three groups of predialysis, hemodialysis, and peritoneal dialysis patients).
second group compared EPO treatment with no EPO treatment. Overall, trials that were pooled in this second group resulted in lower Hb levels achieved in both the intensive and control arms than the Hb levels in the corresponding arms in the first group of trials. On the basis of these considerations, the results of these two groups of studies were analyzed separately. Of note, follow-up duration was higher and publication date was more recent in the first group of trials. These trials seemed more generalizable to current practice, whereas those done earlier seemed to be conducted mainly to demonstrate dose-response relationships and safety of EPO treatment.
Trial Quality
Trial quality was variable. Allocation concealment was unclear in all 19 trials. Outcome assessors were not stated as blinded in any of the trials, and only three studies were analyzed on an intention-to-treat basis. The dropout rate ranged from 0.0 to 57.8%.
Trial Results
All-Cause Mortality. In the high Hb target versus low Hb target trials, there was a lower risk of death with the lower Hb target compared with the high Hb target (four trials, 1949 patients; RR, 0.84; 95% CI, 0.71 to 1.00; P ϭ 0.05). This analysis was dominated by the Besarab et al. (16) study, contributing 86.2% of the weight. There was no heterogeneity across these trials (heterogeneity 2 ϭ 0.59, P ϭ 0.8, I 2 ϭ 0%; Figure 2 ).
In the trials of EPO treatment versus no EPO treatment, there was no statistically significant difference in the risk of all-cause mortality between the two arms (three trials, 255 patients; RR, 1.83; 95% CI, 0.48 to 7.06). Heterogeneity across these trials was also not significant (heterogeneity 2 ϭ 0.45, P ϭ 0.8, I
2 ϭ 0%). Seizures. This outcome was reported only in the trials of EPO treatment versus no EPO treatment, and we obtained additional data of the Besarab et al. (16) Figure 3 ). Hypertension. Eight studies provided data on the number of patients who had hypertensive episodes and required additional antihypertensive medication or exclusion of patients from the trial because of hypertension. Two of these were from the group of trials that compared high versus low Hb targets, and six were from the group of trials of EPO treatment versus no EPO treatment. No significant difference for hypertension was demonstrated between the two Hb targets in the first group of trials (two trials, 1277 patients; RR, 0.92; 95% CI, 0.59 to 1.45). Heterogeneity was not significant across these trials (heterogeneity 2 ϭ 1.41, P ϭ 0.24, I 2 ϭ 29.0%). There was a significantly lower risk of hypertension in the EPO treatment arm compared with no EPO treatment in the second group of trials (six trials, 387 patients; RR, 0.50; 95% CI, 0.33 to 0.76; P ϭ 0.001). Heterogeneity in this group of studies was not significant (heterogeneity 2 ϭ 2.88, P ϭ 0.72, I 2 ϭ 0%; Figure 4) .
Quality of Life. Many problems were evident in the evaluation of these data. Five of 10 trials in which quality of life or exercise capacity was analyzed did not use validated scales for the assessment of quality of life (i.e., codified scales for the assessment of quality of life or exercise capacity such as the Short Form-36 or the Kidney Disease Quality of Life questionnaires, which have been validated using standard methods and in relevant populations) (24, 27, 30, 32, 36) . Also, dimension-specific and composite quality-of-life outcomes reported were not prespecified, and only positive results were presented. When codified scales were used, overall scores presented were Figure 2 . Effect of high versus low hemoglobin (Hb) targets on all-cause mortality. not described in detail. Commonly, individual items of quality of life that had improved with the higher Hb target were reported as an indication of an overall positive effect of the higher target, or else a positive effect of EPO treatment on quality of life. It was not possible to perform a pooled analysis given the wide variability of the assessment of these outcomes and uncertainties regarding the validity of the instruments used (Table 3) .
Summary data for all other patient-relevant outcomes (myocardial infarction, serious cardiovascular events [including angina, atrial fibrillation, and severe arrhythmia], stroke, hyperkalemia, access thrombosis, hospitalization rates and days of hospitalization, left ventricular hypertrophy, systolic BP, diastolic BP, and mean arterial pressure) were also analyzed, although minimal data were available. These analyses showed no significant difference between lower and higher Hb targets or EPO treatment and no EPO treatment in relation to any of the outcomes (Table 4) . Of note, data on the effect of EPO on serum creatinine were available in only four trials of EPO treatment versus no EPO treatment, and there was no significant effect (four studies, 77 patients; weighted mean difference, 0.01; 95% CI, Ϫ1.21 to 1.22). Two trials of the high versus low Hb target group indicated a significantly better creatinine clearance at the end of the trials in the lower Hb target arms (two trials, 167 patients; weighted mean difference, Ϫ1.07; 95% CI, Ϫ2.10 to Ϫ0.05).
Discussion
Key Findings
We find that on the basis of available randomized, controlled trials, Hb targets of Ͻ120 g/L are associated with a lower risk of death in the population with cardiovascular disease and CKD compared with Hb targets of Ͼ130 g/L (RR, 0.84; 95% CI, 0.71 to 1.00). In absolute terms, the risk of death is 3.0% (95% CI, 1.0 to 6.0%) lower in the group of patients with Hb target of Ͻ120 g/L compared with the group of patients with Hb target Ͼ130 g/L. For every 30 patients treated to an Hb target of Ͻ120 g/L compared with an Hb target of Ͼ130 g/L, approximately one death is avoided.
The present findings are applicable mainly to hemodialysis patients with clinical cardiovascular disease because the majority of patients included in these trials had these attributes (44 -46) . Higher Hb targets have been recommended in other CKD populations (e.g., CKD stages 3 to 4 or individuals without overt cardiovascular disease) despite the absence of randomized trial data. If higher Hb targets really reduced mortality, then this should be even more evident in studies that include high-risk patients, as those enrolled in the Besarab et al. (16) trial. However, the most favorable interpretation of the Besarab et al. study can be only that there was no survival benefit demonstrated. To find a survival benefit in lower risk patients would be more difficult because a larger number of individuals would have to be studied to have adequate power, and empiric evidence of qualitative effect modification (i.e., harm in one group and benefit in another using the same intervention) is very rare (47) . The finding of higher mortality in higher Hb target groups from very recent cancer trials would also make a survival benefit of higher Hb values in the CKD population very unlikely (19) . The annualized mortality rate in the 1233 patients of the Besarab et al. study was 24%, which is very similar to the annualized mortality rate for every 1000 patients (20.4%) reported by the United States Renal Data System (http://www.usrds.org), suggesting that results from this trial are in fact generalizable.
Lower Hb targets of Ͻ95 g/L in individuals who are not treated with EPO are associated with a significantly increased risk of seizures (RR, 5.25; 95% CI, 1.13 to 24.34) compared with treatment with EPO and Hb values of Ͼ100 g/L. In absolute terms, the risk of seizures is 4% (95% CI, 3 to 10%) lower with Hb values of Ͼ100 compared with the group of patients with Hb Ͻ95 g/L. This means that for every 25 patients treated to an Hb level of Ͼ100 g/L, one fewer will develop seizures.
Finally, lower Hb levels of Ͻ95 g/L with no EPO treatment are associated with a reduced risk of patients who present with hypertensive episodes (RR, 0.62; 95% CI, 0.42 to 0.92). In absolute terms, the risk of developing hypertensive episodes is 16% lower (95% CI, 8 to 24%) with Hb values Ͻ95 g/L compared with Hb Ͼ100 g/L. For every seven patients treated to obtain an Hb Ͼ100 g/L, one patient will require additional antihypertensive medication.
Comparison with Other Studies
This systematic review is influenced mainly by the finding of Besarab et al. (16) of an association of higher mortality in individuals who have cardiovascular disease and are treated to Hb targets Ͼ130 g/L. The other small trials are inadequately powered to show any evidence of benefit or harm, both separately and combined (RR, 0.98; 95% CI, 0.61 to 1.55). They show no difference between the arms that treated to higher Means are provided for continuous variables; lower and higher mean is provided for analyses including more than one trial.
versus lower Hb targets, although the CI do not exclude benefit or harm. Seizures are reported to be a complication of EPO in the product information. However, this systematic review indicates that treating with EPO may be protective against seizures. There is some uncertainty with this finding as a result of the small number of trials reporting this outcome; a small number of patients were present in each Hb target group, and very small number of events were reported. The physiologic rationale underlying the protective role of EPO against seizures could be the increased peripheral cerebral oxygenation of neurons and the observation that neurons develop EPO receptors during ischemia, with a neuroprotective effect of EPO independent of its effects on Hb (48) .
Hypertension is a widely known adverse effect of EPO treatment, and our review confirms this finding (9) . Access thrombosis is another recognized complication of EPO treatment, although the results in the available studies are conflicting. In our review, we found that the Besarab et al. (16) study showed a significantly higher risk of access thrombosis with the higher Hb target, whereas the remaining trials did not confirm this finding.
Reports of stroke episodes in the available trials in individuals with CKD are few. This aspect mandates further investigation, in light of available data suggesting that EPO promotes thrombosis by interaction with platelet function (49) . A recent trial of EPO versus placebo in breast cancer patients was terminated prematurely because of significantly higher mortality in the group that was treated with EPO, as a result of an increase in the incidence of thrombotic and vascular events and breast cancer progression in the EPO-treated patients (50) . Another placebo-controlled trial of EPO in patients with head and neck cancer found that EPO ␤ corrects anemia, but there was a significantly higher number of deaths in patients in the EPO arm (51) . A recent editorial in Lancet Oncology reported similar findings from other still unpublished studies (19) . The applicability of these results to CKD patients is unclear but a cause of concern.
EPO is widely reported to improve quality of life. We could not pool results on quality of life; nonvalidated scales were often used, and authors reported individual domains of a quality-of-life scale, which were significantly different, without prespecification, rather than report the summary measure of effect, suggesting outcome reporting bias (52) .
Many narrative reviews and some meta-analyses have been published on this debated topic. Two Cochrane systematic reviews of randomized trials of EPO use or Hb targets for anemia of CKD are consistent with the present larger analysis that includes the most recently published trials (53, 54) . Our study's findings are also consistent with the results of an Agency for Healthcare Research and Quality report on EPO use for anemia of CKD (55) . This report, which was also based on randomized, controlled trials, concluded that there is not strong evidence showing that maintaining Hb Ͼ120 g/L is more beneficial to CKD patients than Hb Ͻ120 g/L. Compared with ours, the Agency for Healthcare Research and Quality report did not include some recently published trials and did not consider seizures as an outcome, and there was no standard quality assessment of the included trials. The most recently published is a "systematic review" of the impact of epoetin ␣ on clinical end points in patients with CKD (50), which suggested that epoetin ␣ therapy provides important clinical and quality-of-life benefits while substantially reducing hospitalizations and transfusions. This study had the following limitations: It did not fulfill standard requirements for systematic reviews, as it lacked clear inclusion criteria and an explicit and comprehensive search strategy; it included both randomized and cohort studies; and there was no quality assessment of included studies. We conclude that on the basis of available data from randomized trials, it is not possible to draw evidence of improvement in quality of life, hospitalizations, and transfusions.
Strengths and Weaknesses
Although there are many studies and reviews on this debated topic, this is the most updated systematic review of randomized trials reported. Our findings contrast with data from large observational studies that have shown a consistent association between higher Hb values and improved outcomes, including increased survival (56) . This discrepancy between observational and trial data are well recognized. Observational studies are not the best study design to answer intervention questions, because of bias and confounding, the effects of which are unpredictable and may result in an overestimate, an underestimate, or true estimate of effect (57) . In this setting, observational studies may well be flawed as a result of residual confounding such that the higher Hb values may reflect underlying better survival potential as a result of an inability to adjust completely for all known and unknown predictors of survival. In short, healthier patients (with higher Hb values) live longer. Only randomized trials can show whether changing Hb values improves survival, because any baseline predictors of survival should be balanced between treatment arms as a result of the randomization. Recent examples of the unpredictable biased nature of observational studies include the findings of the ADEMEX and the HEMO Study (randomized trials), which contrast with the results of the CANUSA (observational) study (58, 59) .
It is important to point out the potential reasons for heterogeneity in the studies included in these analyses to understand the limitations of the conclusions that can be derived from them. These differences, which include variable sample size, treatment protocols (treatment targets or EPO interventions), populations studied, follow-up times (16, 42) , deficiencies in design, and reporting of the published trials, all were made explicit in this study but did not result in statistically significant heterogeneity of any analysis. target should be Ͻ120 g/L. Data relating to other populations (predialysis patients with CKD with and without cardiovascular impairment) are unclear. Higher Hb targets have long been known to be associated with improvement in the quality of life, but available evidence from randomized, clinical trials is problematic. Until additional, well-designed trials that adequately assess safety and quality of life are available, clinicians always need to consider the potential harms and costs whenever prescribing interventions of unproved efficacy.
Future Research
Our study highlights the need for randomized, controlled trials in the area of anemia management in CKD. The concerning results about higher risk of all-cause mortality in patients who have cardiovascular comorbidities and are treated with higher EPO doses in the pursuit of higher Hb targets arise mainly from the most recent trials that had the longest follow-up duration and seem to be more generalizable to current practice than the remaining ones. Adequately powered, welldesigned and reported long-term, randomized, controlled trials comparing the benefits and harms of different Hb levels are necessary. Given the findings of Besarab et al. (16) of increased all-cause mortality with a higher Hb target (Hb ϭ 140 g/L) and the uncertainties of trials in which an average (Hb ϭ 100 to 110 g/L) target was tested, future studies should compare the effect of treatment targets for Hb in the range of 120 to 140 with lower targets, with adequate power, and in different populations (e.g., predialysis CKD patients). Trials of Hb targets could be done with EPO but also the newer agent darbepoetin. Seizures should be reported, and quality of life should be assessed using validated tools. The trials should be adequately powered to detect relevant patient outcomes, including mortality and thrombovascular accidents. With a power of 80%,~1500 patients would be needed in a population with a baseline mortality risk of 15% if we expected the intervention (high Hb target) to reduce mortality to 10%. Approximately 2000 would be needed with a baseline mortality of 20% and an expected reduction to a value of 15%, a 2-yr accrual time and 3-yr follow-up, and an expected noncompliance of~10%. Insights for the management of the anemia of CKD may also derive from the three ongoing randomized trials on the topic (CREATE, CHOIR, and TREAT). Their results are particularly expected to elucidate the potential impact of different Hb targets in predialysis patients with CKD. Additional information on the relationship between Hb values achieved and clinical outcomes could be gleaned from an individual patient data meta-analysis.
